POPULARITY
6 episodes with oncolytic
4 episodes with oncolytic
2 episodes with oncolytic
2 episodes with oncolytic
2 episodes with oncolytic
4 episodes with oncolytic
3 episodes with oncolytic
Wait, viruses as cancer therapy?? That's right! Oncolytic viruses or OVs are a newer and promising type of therapy that uses viruses to take down cancer in a safe manner. But how the HEK do they work? This month we sit down with Dr. Lee-Hwa Tai from the University of Sherbrooke, Quebec to discuss all about OVs. Join us as we dive into how OVs kill cancer, their current status in the clinic, how safety is managed, exciting research in the field, and more! -- Interested in learning more about immunotherapy? Check out our other episodes and give us a follow on instagram @wthisimmunotherapy and twitter @WTHisImmunoT! And check out our new website wthisimmunotherapy.com. Or feel free to reach out to us at wthisimmunotherapy@gmail.com if you have any questions or any ideas for episodes! Access Transcript here. -- Creators & Producers: Gillian Savage, Grace Bernard, and Dr. Pauline Loos Podcast Logo is designed by Mia Portelance Music is by Lara Antebi (https://laraantebi.bandcamp.com/)
Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.ImmVirx has developed a proprietary bio-selected RNA virus that is showing promising pre-clinical and phase 1 results as monotherapy in hard-to-treat cancers, including colorectal, gastric hepatocellular and ovarian cancers.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Do you know how the biosafety risks of oncolytic immunotherapies and their combination with immune checkpoint inhibitors can be mitigated? Credit available for this activity expires: 6/22/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993479?ecd=bdc_podcast_libsyn_mscpedu
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD. Related Content: Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD. Related Content: Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
A new research perspective was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Intraventricular immunovirotherapy; a translational step forward.” In this new perspective, researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman from Harvard Medical School, Massachusetts Institute of Technology and University of Alabama at Birmingham discuss oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV). Intraventricular therapy (IVT) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. “Oncolytic herpes simplex virus type-1 (oHSV) has shown promise in clinical trials in both pediatric and adult brain tumors [6–9].” However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207. “Overall, demonstrating the safety and efficacy of IVT with G207 is a significant step towards expanding the capabilities of oHSV, paving the way for new clinical trials, and increasing the potential of an already promising therapy.” DOI: https://doi.org/10.18632/oncotarget.28343 Correspondence to: Joshua D. Bernstock - jbernstock@bwh.harvard.edu, Gregory K. Friedman - gfriedman@uabmc.edu Keywords: oncolytic virotherapy, herpes simplex virus (HSV), G207, intraventricular therapy, leptomeningeal disease About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Season 3, Episode 13: Oral Oncolytic Nurse Navigator - April Hallatt, BSN, RN, OCNThis week we sit down with April Hallatt, BSN, RN, OCN to discuss her role as Oral Oncolytic Nurse Navigator, the importance of the multidisciplinary team, and how she uses NCODA resources. April is the Oral Oncolytic Nurse Navigator at Indiana University Health Ball Memorial Cancer Center in Muncie, Indiana and is nationally certified in oncology. Along with a multidisciplinary team, she developed a nurse navigation program that patient-centered and focuses on appropriate monitoring and support for all patients while on an oral oncolytic. She graduated with a Bachelor of Science in Nursing from Ball State University, Muncie and has over 18 years of nursing experience. If you would like more information on joining NCODA's nursing committee, please email Natasha.Olson@ncoda.org.
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of injection, and it also trains cells to look for tumor cells migrating throughout the body. Paul Peter explains, "The approach we call oncolytic viral immunotherapy. The name already indicates that we use viruses here for a good purpose, actually, to treat cancer. And immunotherapy indicates that we try to activate the patient's own immune system to fight cancer at the site of the injection, as well as at the site of the un-injected distant metastasis. Basically, you can see it as a form of what we call in situ vaccination. In situ means at the place of the injection." "We kill the tumor cells at the site of the injection, and we do that in a way that's immunogenic. That means that we activate the immune system, and we create the optimal conditions at the site of the injection of the body's own immune system to start to recognize specifically the so-called cancer neoantigens. These are the molecules that are expressed on the surface of the cancer cells, and that can be recognized by these T cells. We call them cytotoxic T cells. The name already means that they're able to kill the tumor cells." #Candel #CandelTherapeutics #Candoers #CAN2409 #Immunotherapy #SolidTumors #Cancer candeltx.com Download the transcript here
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of injection, and it also trains cells to look for tumor cells migrating throughout the body. Paul Peter explains, "The approach we call oncolytic viral immunotherapy. The name already indicates that we use viruses here for a good purpose, actually, to treat cancer. And immunotherapy indicates that we try to activate the patient's own immune system to fight cancer at the site of the injection, as well as at the site of the un-injected distant metastasis. Basically, you can see it as a form of what we call in situ vaccination. In situ means at the place of the injection." "We kill the tumor cells at the site of the injection, and we do that in a way that's immunogenic. That means that we activate the immune system, and we create the optimal conditions at the site of the injection of the body's own immune system to start to recognize specifically the so-called cancer neoantigens. These are the molecules that are expressed on the surface of the cancer cells, and that can be recognized by these T cells. We call them cytotoxic T cells. The name already means that they're able to kill the tumor cells." #Candel #CandelTherapeutics #Candoers #CAN2409 #Immunotherapy #SolidTumors #Cancer candeltx.com Listen to the podcast here
It's common for cancer programs and practices to struggle with timely treatment education, consent gathering, and adherence tracking, especially when an oral oncolytic is prescribed. These challenges are due in part to older solutions that are no longer benefiting all patients equally. To better address these concerns, Baptist Health South Florida, Miami Cancer Institute in Florida turned to technology solutions that were already being used by the health system and that were well understood by their healthcare teams and patients. By using these technologies and implementing existing staffing resources, Miami Cancer Institute staff are providing high-quality cancer care without having to dip deeper into its operating budget. Guest: Morgan Nestingen, MSN, APRN, AGCNS-BC, NEA-BC, OCN, ONN-CG Director of Nursing Services, Patient Intake and Navigation Baptist Health South Florida, Miami Cancer Institute Resources: Improving Oral Oncolytic Compliance with Technology 2022 ACCC Innovator Award Details ACCC 39th National Oncology Conference Care Coordination: The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics Leveraging Pharmacy Informatics to Standardize Pharmacists' Review of Oral Oncolytics for Hospitalized Patients Defining the Role of Oncology Advanced Practitioners Improve Oral Oncolytic Workflow and Reduce Treatment Delays with a Pharmacist Collaborative Practice Agreement This podcast is part of a special series on the 2022 ACCC Innovator Award winners. For a deeper dive into this content, visit ACCC's Innovator Award website.
Dr. David Kirn MD, is the founder, CEO and Chairman of Ignite Immunotherapeutics, which was recently acquired by Pfizer. David is a Physician-scientist and a serial biotech entrepreneur with over 25 years of experience in the industry with a focus on viral vector-based therapeutics including gene therapy and oncolytic virus cancer immunotherapy. We talk about acquisition models in the pharma and biotech industries; the origins of the idea behind Ignite, how the relationship with Pfizer was initiated in a novel “Build to buy” model; details of how the relation worked; benefits of working with big pharma, and how startups should think about such relationships. Show notes: 1. Business models for biotech companies 2. Oncolytic viruses to attack tumors and stimulate patient specific immune response 3. 100 year old technology to use viruses to lyse cancer cells 4. Onyx pharmaceuticals and use of Adenoviruses 5. Viruses didn't evolve enough to destroy cancer cells completely 6. Traditional nude mice not good enough for predicting behaviour in humans 7. PDX or mouse tumor models with intact immune systems slightly better- not one mode is good enough 8. Viruses good for oncolytic capabilities: Large transgene carrying capacity 9. Systemic delivery is important 10. Financing biotech startups- strengths and weaknesses 11. Pharma partnerships: Things to consider and how Ignite arrived at agreement to work with Pfizer (https://www.fiercepharma.com/vaccines/pfizer-backs-cancer-vaccine-startup-ignite-immunotherapy) 12. Terms of the business agreement 13. The role that Pfizer played in the relationship, and the acquisition 14. Track record and connections help with partnerships 15. Way to think about fundraising, success, resources in biotech startups 16. Mistakes to avoid and lessons learnt from partnering with big pharma/biotech
Listen to a blog summary of a trending research paper published by Oncotarget in Volume 13, entitled, "Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma.“ ______________________ Multiple myeloma (MM) is a currently incurable cancer of blood plasma cells. Autologous stem cell transplantation (ASCT) has had efficacious results among eligible patients. However, even after ASCT, a significant number of patients continue to relapse and become resistant to current standard therapies. A promising new method to treat blood cancers is a form of immunotherapy called virotherapy. Oncolytic viruses are uniquely capable of being reprogrammed to selectively infect and kill various cancer cells without infecting or damaging normal cells in host organisms, including mice and humans. Researchers from Arizona State University, Emory University and the Mayo Clinic (in Scottsdale, Arizona) had previously experimented with using the oncolytic myxoma virus (MYXV) to treat MM. In nature, MYXV only affects rabbits and is innocuous in mice and humans. They found that MYXVs delivered through stem cell transplantation can eliminate some residual MM cells in the Balb/c mouse model. “Recently, we reported that ex vivo virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an autologous-transplant Balb/c mouse model.” However, the researchers found that Balb/c mice may not be ideal models for MM. They observed that the behavior of MM in Balb/c mice did not quite reflect the development, clinical manifestation and localization of MM observed in human patients. Therefore, the team conducted a new study of MYXVs in the Vk*MYC transplantable C57BL/6 mouse MM model. Their trending research paper was published in Oncotarget on March 3, 2022, and entitled, “Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma.“ Full blog post - https://www.oncotarget.org/2022/03/17/trending-with-impact-adjunct-virotherapy-fights-multiple-myeloma/ DOI - https://doi.org/10.18632/oncotarget.28205 Correspondence to - Grant McFadden - grantmcf@asu.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28205 Keywords - myxoma virus, multiple myeloma, combination therapy, autologous transplantation, oncolytic virus About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Dr. Paul Peter Tak is the President and CEO of Candel Therapeutics which is focused on educating the immune system to recognize and kill tumor cells in patients with a solid tumor. Candel is developing immunotherapies using engineered oncolytic viruses for prostate cancer, brain cancer, lung cancer, pancreatic cancer, and eye cancer. Paul Peter explains, "Viruses probably got a bad reputation during the pandemic, but you can actually use them to do something beneficial to a patient, and that's what we are doing. So, using molecular engineering, we change the viruses in such a way that they infect the tumor cells and that they induce cell death. They kill the tumor cells in a way that activates the patient's own immune system, which is basically a very natural way to fight cancer." "So, at the same time, we change the so-called tumor microenvironment from a cold tumor, a tumor that is not very active in terms of immune activity, into a hot tumor where we activate a whole variety of immune cells. And that's an optimal way to immunize the patient against the patient's own variety of so-called cancer neoantigens, the molecules that are being recognized by the patient's immune system." #CandelTherapeutics #Oncology #OncolyticVirus #Immunotherapy #LungCancer #ProstateCancer #BrainCancer #Glioma #PancreaticCancer #EyeCancer #Cancer CandelTx.com Download the transcript here
Dr. Paul Peter Tak is the President and CEO of Candel Therapeutics which is focused on educating the immune system to recognize and kill tumor cells in patients with a solid tumor. Candel is developing immunotherapies using engineered oncolytic viruses for prostate cancer, brain cancer, lung cancer, pancreatic cancer, and eye cancer. Paul Peter explains, "Viruses probably got a bad reputation during the pandemic, but you can actually use them to do something beneficial to a patient, and that's what we are doing. So, using molecular engineering, we change the viruses in such a way that they infect the tumor cells and that they induce cell death. They kill the tumor cells in a way that activates the patient's own immune system, which is basically a very natural way to fight cancer." "So, at the same time, we change the so-called tumor microenvironment from a cold tumor, a tumor that is not very active in terms of immune activity, into a hot tumor where we activate a whole variety of immune cells. And that's an optimal way to immunize the patient against the patient's own variety of so-called cancer neoantigens, the molecules that are being recognized by the patient's immune system." #CandelTherapeutics #Oncology #OncolyticVirus #Immunotherapy #LungCancer #ProstateCancer #BrainCancer #Glioma #PancreaticCancer #EyeCancer #Cancer CandelTx.com Listen to the podcast here
In this episode we are focusing on cancer, oncolytic viruses and how investor mindset helps building successful biotech companies. Our guest today is Arthur Kuan, the CEO of CG Oncology. Arthur is a molecular biologist by training. After completing his undergraduate training, Arthur started his career as a venture investor working at several prominent Shanghai-based funds focusing on the Healthcare industry. In 2016, Arthur became the CEO of CG Oncology, one of the portfolio companies of Ally Bridge, the investment fund he was working at the time. In this interview, Arhtur shares his story of becoming a CEO and explains the challenges of bringing a promising scientific idea into clinics.Together with Arthur we discussed:◦ Arthur's journey from investor to CEO◦ The place of oncolytic viruses on the map of cancer therapeutics◦ Combinational therapies for cancer◦ Partnerships between emerging biotech startups and large pharma◦ Differences in the mindset between investors and founders◦ What it takes to lead a successful biotech company today◦ Arthur's vision for the future of personalized cancer treatmentGet in touch with Arthur:◦ Twitter: https://twitter.com/cgoncology, https://twitter.com/KuanArthur ◦ LinkedIn: https://www.linkedin.com/in/arthurkuan/ ◦ Web (CG Oncology): https://www.cgoncology.com/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com
As the treatment of cancers has moved toward an increasing emphasis on the role the immune system can play in fighting tumors, a range of new ways to enlist and train the immune system have emerged. Candel Therapeutics is developing oncolytic viral immunotherapies, which it says combines anti-tumor activity while also stimulating the immune system. We spoke to Paul Peter Tak, president and CEO of Candel Therapeutics, oncolytic viral immunotherapies, how they work, and why they may be able to bring benefits to the treatment of a range of solid tumors.
This episode is also available as a blog post: https://mdforlives.blog/2021/07/19/oncolytic-virus-is-coming-for-cancer-cells/ --- Send in a voice message: https://anchor.fm/mdforlives/message
A Welcome Virus: Cracking the Viral Code for the Battle Against Cancer Chairman and founder of PsiVac, Prof. Ghassan Alusi, and the chief operating officer, Imad Mardini, discuss how the company's proprietary oncolytic virus platform offers new hope for cancer patients. During a time when everyone actively fears viruses (especially THE virus) and their mutations, it is only cancer cells that have cause to worry about oncolytic viruses, and rightly so. These mutated viruses are administered directly into a tumor. Once inside, they crack open the tumor's cells in a process known as lysing that provokes a strong response from the body's immune system, which has, until then, ignored the cancerous cells. What's more, the therapy's attack doesn't stop at a single tumor. The replicating and lysing viruses release previously hidden tumor-associated antigens (TAAs) that alert the immune system about cancer cells to attack all over the body. The body's own immune system then goes on to destroy previously unrecognized tumors far removed from the initial injection point. The biotech company PsiVac advances this technology even further by creating a treatment platform that transforms the adenovirus, aka the common cold, into an especially powerful oncolytic virus. A precision modification in the virus's DNA improves its efficiency against cancer cells while making it harmless to other cells, rendering the treatment at once more effective and safer for patients. “Now that the technologies of other forms of immunotherapy are gaining ground, and as cancer remains a major cause of mortality, we now understand there is a huge need for oncolytic viral therapy,” says Prof. Alusi, whose company has planned to start Phase 1 clinical trials later this year. Unlike other immunotherapies, such as patient-centric CAR T-cell therapy, oncolytic viruses can be made in relatively large quantities once their efficacy and safety have been proved. Curious to Know More? In the first episode of the new season of the podcast A View On, host Martina Ribar Hestericová discusses the current state of oncolytic viruses and their promising applications with Prof. Ghassan Alusi and Imad Mardini. KEY TERMS: Cell lysing is the process of breaking down a cell's membrane, destroying the cell and releasing its contents into the body. If an oncolytic virus lyses a cell, it releases replicated versions of itself as well as antigens helpful in the immune system's fight against a tumor. Tumor-associated antigens (TAAs) are released once a cancer cell is lysed, setting the previously dormant immune system into action. The release of TAAs means that the tumor is no longer successfully hiding from the immune system, and the body can begin to fight the disease by its own means. The cytotoxicity of a virus is the extent to which a virus attacks and destroys cells, often an undesirable event. However, with oncolytic viruses, this cytotoxicity works in a patient's favor, thanks to gene editing, by being specifically designed to attack cancer cells. An agnostic oncolytic virus targets not only one or a group of cancers but is effective against all malignant solid palpable tumors. PsiVac's modified adenovirus has proven agnostic so far, making it a powerful weapon in the fight against cancer.
Dr. Carolini Kaid, Ph.D. is the Co-Founder & CSO at Vyro Biotherapeutics (https://en.vyrobio.com/), a Brazilian biotechnology company focused on developing cancer-killing, or ‘oncolytic' viruses (OVs) designed to target pediatric and adult brain cancer. Dr. Kaid is also a Postdoctoral Fellow at Center for Human Genome and Stem Cell Studies, at The University of São Paulo (USP), a public university in the Brazilian state of São Paulo, which is the largest Brazilian public university and the country's most prestigious educational institution (https://bv.fapesp.br/en/pesquisador/6...). Dr. Kaid has her Ph.D. in Cancer Genetics, a Master's degree in Cancer Biology, and an undergraduate degree in Genetics, all from USP. Dr. Kaid completed 10 years of experience in cancer biology research, including CNS tumor research, tumor stem cells, and advanced therapies. During her MsC, Dr. Kaid worked with miR-367 as a biomarker for aggressive pediatric cancer and potential therapeutic target, which led to the 2015 Award of Scientist and Entrepreneur of the Year, by Nanocell Institute. As a PhD student, under the mentorship of Dr. Oswaldo Keith Okamoto, she acquired a broad background in pre-clinical models, with specific training and expertise in cell culture, brain histology, molecular genetics, stereotaxic surgery, and stereology. Her PhD Thesis, was awarded with Brazil's Best PhD Thesis 2020, resulting in two patent applications and pre-clinical findings that opened opportunities for future translational studies to evaluate new putative biomarkers of aggressive stem-like tumor cells in refining diagnosis, patient stratification, and early detection of relapsed disease. Her work also revealed novel therapeutic approaches, using an miR-367 inhibitor and the oncolytic Zika virus, both targeting the stem-like tumor cells that could benefit patients affected by CNS tumors lacking effective treatment. Recently, as postdoctoral fellow at Human Genome and Stem Cell Research Center, under Dr. Mayana Zatz supervision, she continues to investigate alternative immunotherapies with a focus on oncolytic viruses and is coordinating a veterinary clinical trial using the oncolytic Zika virus in dogs with advanced brain tumors.
This episode, supported by Bethyl, delves into the realm of the tumor microenvironment (TME), exploring the cells that reside there and how they interact to promote tumor growth and metastasis. Discover how immune cells are attracted and manipulated by tumor cells enabling the cancer to invade neurons where they can then travel throughout the body. Providing an expert's insight into this topic is Moran Amit, Assistant Professor at the MD Anderson Cancer Center (TX, USA). Moran exposes the nebulous interactions in the TME and describes the techniques that he uses to interrogate it, in the hope that by further understanding these interactions we will be able to design more successful, targeted therapies for neurotropic cancers. Contents: · Introductions: 00:00-01:20 · The key cells of the TME: 01:20-02:50 · How cells of the TME support the tumor: 02:50-05:45 · How cancer cells influence and impact immune cells: 05:45-07:25 · The invasion of cancers into the neurons: 07:27-9:45 · Recruitment of neurons to the TME: 09:45-10:55 · The evolution of neuron recruitment to the TME: 10:55-15:00 · Techniques involved in the study of the TME: 15:00-17:00 · Tips for best practice: 17:00-18:00 · Tumors with neural networks: 18:00-20:05 · Clinical impact of research: 20:05-21:50 · The cancers impacted the most by this research: 21:50-23:25 · The impact of neural invasion on patients and neurons: 23:25-25:30 · One thing to improve our understanding of the TME: 25:30-28:00
WATCH THE VIDEO WEBCAST HERE: https://youtu.be/OSftR6JhEtY As Brain Tumor Awareness Month draws to a close, we bring you a new TWIPO episode on the subject. Hosts Dr. Timothy Cripe & Dr. Brenda Weigel are joined by Dr. Gregory Friedman from the University of Alabama in Birmingham to discuss his recently published paper “Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.” Listen in as Dr. Friedman discusses the findings of this phase 1 clinical trial and the progress of oncolytic virotherapy in pediatric brain tumors. You can access the abstract to Dr. Friedman's paper here: https://pubmed.ncbi.nlm.nih.gov/33838625/ Have any thoughts? Questions? Ideas for future topics? Email us at TWIPO@solvingkidscancer.org. Subscribe to TWIPO to get notifications of new uploads. Want to listen to TWIPO's past episodes? Visit www.solvingkidscancer.org/podcast
This episode, supported by Bethyl, delves into the realm of the tumor microenvironment (TME), exploring the cells that reside there and how they interact to promote tumor growth and metastasis. Discover how immune cells are attracted and manipulated by tumor cells enabling the cancer to invade neurons where they can then travel throughout the body.Providing an expert's insight into this topic is Moran Amit, Assistant Professor at the MD Anderson Cancer Center (TX, USA). Moran exposes the nebulous interactions in the TME and describes the techniques that he uses to interrogate it, in the hope that by further understanding these interactions we will be able to design more successful, targeted therapies for neurotropic cancers.Contents:· Introductions: 00:00-01:20· The key cells of the TME: 01:20-02:50· How cells of the TME support the tumor: 02:50-05:45· How cancer cells influence and impact immune cells: 05:45-07:25· The invasion of cancers into the neurons: 07:27-9:45· Recruitment of neurons to the TME: 09:45-10:55· The evolution of neuron recruitment to the TME: 10:55-15:00· Techniques involved in the study of the TME: 15:00-17:00· Tips for best practice: 17:00-18:00· Tumors with neural networks: 18:00-20:05· Clinical impact of research: 20:05-21:50· The cancers impacted the most by this research: 21:50-23:25· The impact of neural invasion on patients and neurons: 23:25-25:30· One thing to improve our understanding of the TME: 25:30-28:00 See acast.com/privacy for privacy and opt-out information.
Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.
Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.
Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.
Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Stephen Russell, CEO of Vyriad. Dr. Russell reveals invaluable insights for those looking for or currently putting together partnership deals. Stephen shares his journey from academia at the Mayo Clinic to founding Vyriad, and eventually partnering with Regeneron for the development of new oncolytic virus treatments for cancer. Learn how Vyriad pivoted their technology to develop antibody tests for COVID-19 during the crisis. See acast.com/privacy for privacy and opt-out information.
In episode 6 we are addressing one of the hottest topics in modern medicine – Immuno Oncology, together with Dr. Stefaan van Gool. Stefaan is a Medical Director of Translational Oncology at the Immunooncological Clinical Center in Cologne, Germany. IOZK is one of the most advanced institutions of this kind in the country. Stefaan has more than 25 years of experience in clinical oncology and related basic research. He has co-authored more than 150 research papers on the relationship between the immune system and cancer.Together with Stefaan we have discussed:◦ The rise of Immuno Oncology◦ How to activate patient’s immune system to fight cancer◦ Personalized treatment of cancer◦ The development of vaccine IO-Vac◦ Advantage of checkpoint inhibition therapy◦ Oncolytic viruses as the anti-tumor agents◦ How to determine the type of therapy for certain cancer◦ Types of tumours most susceptible to immunotherapy◦ The patient journey while treated with IO-Vac◦ Biggest challenges in integrating immunotherapy into routine clinical practice◦ The outlook of the future of personalized medicine and its role in oncologyGet in touch with Stefaan:◦ Linkedin: @Stefaan Van Gool◦ Web (IOZK: https://www.iozk.de/en/)
Oncolytic viruses are cancer-killing viruses engineered to target and replicate in cancer cells and leave normal cells unharmed. They can also alert the immune system to attack the cancer cells. Susanne Warner, MD, is conducting research around a novel cancer-killing virus that can attack tumors in three different ways: by infecting tumor cells, by shutting down blood supply to the tumor, and by training a patient’s immune system to attack the tumor. Dr. Warner is also a surgical oncologist, and she has a deep interest in patient care that goes beyond the operating room – she talks at length about helping patients through their emotional and spiritual journey. Susanne Warner, MD, is Assistant Professor in the Division of Surgical Oncology and Department of Surgery at City of Hope. 2:07 – What is an oncolytic virus? 3:09 – How do they find cancer cells and how do they kill them? 7:17 – How do you make an oncolytic virus in the lab? 8:53 – One of the ongoing debates in the scientific community about oncolytic viruses “The ideal oncolytic viruses in our opinion are potent, quickly dividing and then what we call immunogenic. And that means that the type of tumor cell destruction that they cause makes a splash, essentially, and gets the attention of the immune system so that it can mount an anti-viral response, which then is also a robust anti-tumor response if enough of those tumor cells have been destroyed and revealed themselves to the immune system.” 11:41 – Why the immune system doesn’t just respond on its own to cancer, and how oncolytic viral therapy can rip a hole in the “invisibility cloak” that cancer cells wear 14:07 – The promise of clinical therapies combining immunotherapy with oncolytic virus therapy 17:24 – The surgeon-patient relationship and her interest in helping patients in their spiritual and emotional journey 21:55 – Her message for cancer patients and survivors 25:08 – The impact of ACS funding on her career
Cancer Grand Rounds Lectures from the Norris Cotton Cancer Center Podcasts
Norris Cotton Cancer Center Grand Rounds presented on June 19, 2018 Michael A. Barry, PhD Professor, Mayo Clinic
085 | When it sounds more sci-fi than fact Welcome to another episode of Biotechnology Focus radio! I am your host – Michelle Currie – here to give you the rundown on what’s happening on the Canadian biotech scene! This week we have some revolutionary research happening at the Centre for Drug Research and Development that sounds more sci-fi than fact, a treatment that allows the patient to breathe life back in, therapy that fits like a glove, and an over-the-counter drug that may be able to ward off Alzheimer’s disease. Listen in to find out more! +++++ Empirical observations over the past many decades have suggested that certain types of virus infections could lead to cancer regression. However, the use of so-called oncolytic viruses (OV) with the intent to treat cancer had been met with skepticism. Now, thanks to technological advancements in genetic engineering and virus manufacturing, oncolytic virotherapy has gained considerable attention and demonstrated significant, though perhaps limited, clinical successes. The Centre for Drug Research and Development (CDRD) have been working on ways to potentiate the utility of oncolytic viruses for cancer therapy in the hope that one day these strategies may be able to eliminate, or at the very least significantly reduce the need for traditional cytotoxic chemotherapy. Reducing the use of toxic treatments that impair the patient’s immune system is expected to lead to better overall survival and quality of life for countless cancer patients. Dr. Ismael Samudio, Head of Biologics at the Centre for Drug Research and Development, has been preoccupied on how best to translate oncolytic virus strategies to the clinic, and in particular how to make these viruses work better in combination with targeted agents regardless of whether they are small molecules or antibodies. As Samudio explains, “We are cognizant that such a thing as a magic bullet for cancer is unlikely to exist. Pre-empting that, our work on oncolytic viruses is really trying to find the tools that we could take to the clinic (small molecules, antibodies) to make these agents successful in more cancer patients.” Oncolytic viruses are a very powerful way to combat cancer. They are mostly genetically engineered to specifically target and kill cancer cells, without having an adverse reaction to the patient. They are also known for inducing an immune response against the cells they infiltrate. Currently, the Centre for Drug Research and Development is working with two distinct types of oncolytic viruses. One of them is the precursor of Maraba – a potent engineered virus currently in clinical trials. The Centre is not aiming to treat one particular type of cancer and hopes that their research will effectively work in multiple tumour types. Tumour cells, in general, have defective antiviral responses, and that’s why oncolytic viruses preferentially infect them. Cancer cells do not like to stop making proteins. They’re constantly growing and constantly making proteins. Normal cells have mechanisms that stop uncontrolled growth and protein synthesis. Because those mechanisms are defective in cancer cells, viruses infect them and they don’t have a way to shut down the production of the virus, resulting in massive viral expression and death of the infected tumour cells. Some cancer cells are more sensitive than others to oncolytic viruses, and understanding how to improve the efficacy or these biological agents is paramount to their success in the clinic. The Centre so far has seen successful infection in every single cancer line that they have tested. Some cancer cells, however, tend to be able to escape death induced by the oncolytic virus, and thus in collaboration with several researchers, the centre for drug research and development is developing strategies to increase infectivity and engagement of the immune system. The Centre doesn’t expect that there’s going to be infection of normal tissue. Nonetheless, they remain focused on delivering the treatment to where it needs to go – the tumour. There is no reason if your heart is healthy, or your kidney or liver, to expose those organs to our chemo-biological interventions – whether small molecules or antibodies – and reduce the safety of the approach. They want to make sure that those interventions go to the tumour tissue. The centre expects for some of these efforts to take at least ten years to reach the clinic. Drug development can be a very daunting process, and of course, scientists and clinicians want to make sure it passes all safety and efficacy standards. The centre for drug research and development is a unique organization that focuses on a number of therapeutic areas, including cancer, auto-immune diseases, infectious diseases, neurodegenerative diseases and neurobiology in general. The knowledge gained at the Centre through innovative approaches, outside-the-box thinking, and cross-pollination of disciplines will ultimately lead to life-saving therapies. Oncolytic viruses are such an amazing tool. They can, directly and indirectly, inhibit cancer progression, and I expect them to eventually become a mainstay in cancer therapy. +++++ There has been substantial research coming out of the woodworks from across the country in so many areas of health. But, when you are living with a disease and finally find that medication which makes you feel like yourself again, there is truly nothing like it. This was the case for Jennifer Falkiner. She had been diagnosed with asthma in her thirties and that progressed over time to severe asthma. Even the simple things we all take for granted became difficult, and little joys such as going to the movies, or having a solid nights sleep were taken away from her. It is only now participating in an innovative clinical trial for severe uncontrolled asthma with the use of Fasenra – a respiratory biologic – and the research of Dr. Mark Fitzgerald, primary researcher of the study, that her quality of life and her motivation has returned. “It has been a transformation,” Jennifer says. In the beginning, she wasn’t aware that she even had asthma. Starting as just a respiratory infection, her doctor gave her antibiotics and a puffer, but the infection was persistent and happened again and again. It was only upon going to another doctor that she was informed that she had asthma. Over the years, Jennifer was put on a slew of puffers and medications and yet she still could not stop coughing – making social life, family, and work scenarios trying, and arduous at times. Jennifer told me, “When I was much younger, before the asthma hit, I used to go tobogganing with my children. Then, I had grandkids come along and I couldn’t do that – but now I can. I got on this drug trial and now nothing stops me.” The CALIMA trial was one of three pivotal trials to reduce severe exacerbation requiring prednisone and has shown a 50 per cent reduction in patients who had the active treatment in lieu of the placebo. Fasenra is the only respiratory biologic that provides direct, rapid and near-complete depletion of blood eosinophils from the first dose. Around the world, asthma affects 315 million people, including an estimated 3 million Canadians. Roughly 250,000 Canadians live with severe, uncontrolled asthma, which can have a debilitating impact on lung function and quality of life. Many of the current medications also come with countless side effects, that may deter the people who need the medication from taking it at all. Prednisone, for example, has been known to affect sleeping patterns, weight gain, severe depression, bloody or tarry stools, slow wound healing, dizziness – just to name a few. Fasenra, on the other hand, has had minute reported adverse reactions and is taken every eight weeks after the initial three doses. Dr. Mark Fitzgerald hopes that in the future there will be blood or sputum tests to better identify the treatment that will work for each individual. We’re at a very exciting stage because, hopefully, these drugs will not only be used in patients with severe disease but also can be used earlier in the patient’s history of asthma to maybe modify the trajectory and prevent the progression to more severe disease. Fasenra has been approved by Health Canada and represents a significant milestone for severe eosinophilic asthma patients, finally offering a new treatment option to help manage their condition. The change for Jennifer has been dramatic. Going from a place where walking in the heat, scents, and the constant fear of the inability to breathe depicted what she could and could not do with her life, to now swim, skate, kayak, and play with her grandkids – she has never looked back. +++++ Researchers at Western University have developed custom-fit gloves to help control tremors in patients with Parkinson’s disease. Not only does this glove help give them some sense of normality again, but it gives them their independence back as well. Parkinson’s disease is a long-term degenerative disorder of the central nervous system that tends to affect the motor system the most. The disease progresses slowly over time, and is best exemplified through constant shaking and rigidity. Eventually leading to difficulty walking, swallowing problems and other health conditions. Symptoms may vary from patient to patient. Anybody with Parkinson’s that has tremors have them in their entire body, but it’s the ones in their fingers that really prevent them from performing the activities of daily living. The problem with a lot of the devices that are currently on the market is that they restrict movement in general, which still makes the tasks at hand hard to do. In the worst-case scenario, it can even suppress movement at the level of the elbows or wrists that exacerbates the tremors in the fingers. The design model of the glove uses a system of sensors that track voluntary movements and separates them from involuntary tremors. The gloves will then suppress the tremor to allow fluid motion of movement. The current prototype glove was created for the left hand of student Yue Zhou, who used 3D printing to design a custom fit. The team is also working on improving the glove’s hardware to make it more practical to wear, including reducing the size of the glove’s controller and improving its battery system. Once these pieces are all in place, they hope to find commercial partners to bring the gloves to the market. If effective, this could dramatically change the lives of people living with Parkinson’s disease, allowing them to do daily tasks many people take for granted. +++++ As the general population of the world ages and as diseases like dementia and Alzheimer’s become ever more prevalent, the hunt is on to discover a way to slow their progression or stop it entirely. A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, is now suggesting based upon his empirical research, that if a daily regimen of non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen was started early enough it can prevent the onset of Alzheimer’s disease. This study spells out a simple solution to a vastly complicated neurocognitive impediment. According to the Alzheimer’s Disease International’s World Alzheimer Report 2016, the disease affects 47 million people worldwide, costs the healthcare system more than US$818 billion per year and is the fifth leading cause of death in people over the age of 65. With Canada currently sitting around 560,000 people – a figure expected to rise to 937,000 by 2031 – there is no time to waste. Dr. McGeer, who is president and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. In 2016, McGeer and his team announced that they had created a simple saliva test that can diagnose Alzheimer’s disease as well as predict future onset. The test is based on measuring the concentration of the peptide amyloid beta protein 42 (Abeta42) secreted in saliva. In most individuals, the rate of Abeta42 production is almost very similar regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are inclined to develop Alzheimer’s disease. That is because Abeta42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease. Contrary to the belief that Abeta 42 is only produced in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is fated to develop Alzheimer’s disease. This provides the patient with the opportunity to begin taking early preventive measures, such as consuming over the counters like ibuprofen. Dr. McGeer explains that what they’ve learned through their research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime. Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, they recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42levels then, that is the time to begin taking daily ibuprofen to ward off the disease. Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Their discovery is a game changer. They now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated. +++++ Well, that wraps up another episode of Biotechnology Focus radio! Thanks for listening! If you have any questions or comments, please reach out to us at press@promotivemedia.ca. Tune in next week! From my desk to yours – this is Michelle Currie.
Oncolytic Virotherapy is a form of immunotherapy that is now being tested on malignant brain tumors in children. Dr. Gregory Friedman is the principal investigator for the first-ever pediatric trial of Herpes Simplex Virus (HSV G207) in children with recurrent or progressive brain cancers.The herpes virus, which typically causes cold sores, has been engineered to be safe for normal cells, but can infect and kill cancer cells and stimulate the patient's own immune system to attack the tumor; this provides a "one-two punch" at killing tumor cells. This Phase 1 clinical trial, funded by the National Institutes of Health and the U.S. Food and Drug Administration, is testing the safety and reliability of the virotherapy.To maximize the benefit of this therapy, Dr. Friedman's lab focuses on determining mechanisms of therapeutic resistance by exploring the role of tumor genotype, phenotype, and microenvironment as well as cellular defense mechanisms so that newer viruses, novel combinations, and unique routes of virus delivery may be developed to circumvent resistance mechanisms.Here to discuss Oncolytic Virotherapy is Dr. Gregory Friedman. He is an Associate Professor of Pediatrics at UAB and Children's Hospital of Alabama, and an Associate Scientist at the UAB Comprehensive Cancer Center.For more information click here: Clinical Trial: HSV G207.
Dr Andtbacka meets with ecancertv at WCCS 2016 to discuss the use of oncolytic virotherapy (OV) in the treatment of melanoma. He discusses the OPTiM trials of T-VEC, a genetically modified herpes virus, including identifying which patients have the most durable response, and looks forward to potential combinations for T-VEC and other OVs.
Dr Pandha speaks with ecancertv at ESMO 2016 about two trials of coxsackie virus as an immune modulator. Dr Pandha describes results from the CANON trial of virotherapy for bladder cancer, and the STORM / KEYNOTE200 trial which combined virotherapy with immune modulator pembrolizumab. He describes how viral stimulation of immune activity, further enhanced by checkpoint inhibitors, can have significant outcomes, and considers wider adoption of virotherapy to complement other treatment modalities.
Design of a synchronously lysing bacterium for delivery of anti-tumor molecules in mice, and hopanoids, the lipids that live forever, brought to you by the four Microbies of TWiM. Hosts: Vincent Racaniello, Elio Schaechter, Michael Schmidt, and Michele Swanson. Subscribe to TWiM (free) on iTunes, Stitcher, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Links for this episode Bacterial lysis for in vivo delivery (Nature) Coley’s toxins (Iowa Orthop J) Hopanoids, stress tolerance, and nutrient storage (Geobiol) Lipids that last forever (STC) Fattening up microbial geological biomarkers (STC) Money spreads infection (Fut Micro) This episode is brought to you by CuriosityStream, a subscription streaming service that offers over 1,400 documentaries and nonfiction series from the world's best filmmakers. Get unlimited access starting at just $2.99 a month, and for our audience, the first two months are completely free if you sign up at curiositystream.com/microbe and use the promo code MICROBE. This episode is also brought to you by Drobo, a family of safe, expandable, yet simple to use storage arrays. Drobos are designed to protect your important data forever. Visit www.drobo.com to learn more. Listeners can save $100 on a Drobo system at drobostore.com by using the discount code Microbe100. Send your microbiology questions and comments (email or mp3 file) to twim@microbe.tv
Hosts: Vincent Racaniello, Rich Condit, and Kathy Spindler Guest: Stephen J. Russell From ASV 2016 at Virginia Tech, Vincent, Rich and Kathy speak with Stephen Russell about his career and his work on oncolytic virotherapy - using viruses to treat cancers. Become a patron of TWiV! Links for this episode Hokies go viral (TWiV 285) MV NIS de Myelo (TWiV 298) Remission of disseminated myeloma after MV treatment (Mayo Clin Proc) miRNA detargeting (J Virol) Video of this episode at YouTube This episode is sponsored by CuriosityStream. Get two months free when you sign up at curiositystream.com/microbe and use the promo code MICROBE. Weekly Science Picks Kathy - Can you explain your science in 30 seconds? and How Far Can We Go?Rich - Small asteroid Earth's companionVincent - The Gene by Siddhartha Mukherjee Listener Picks Dylan - Microsculpture by Levon Biss (website) Send your virology questions and comments to twiv@microbe.tv
Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.
Fakultät für Chemie und Pharmazie - Digitale Hochschulschriften der LMU - Teil 05/06
Tue, 27 Jan 2015 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/17911/ https://edoc.ub.uni-muenchen.de/17911/1/Kostova_Youlia.pdf Kostova, Youlia ddc:540, ddc:500, Fakultät fü
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler The TWiV gang reviews ten fascinating, compelling, and riveting virology stories from 2014. Ten virology stories of 2014 Ebola virus outbreak (TWiV 314, 309, 308, 307, 306, 305, 304, 303, 302, 298, 297, 283) Directional uncoating of rhinovirus RNA (TWiV 267) Pandemic pathogen controversy (TWiV 287) Viral evolution (TWiV 275) Borna virus inhibition by endogenous DNA (TWiV 303) MERS-CoV in dromedary camels (TWiV special, TWiV 287) Oncolytic measles virus (TWiV 298) Amazing norovirus findings (TWiV 312 and 313) Toxin delivery to aphids (TWiV 272) The Salk Legacy (TWiV 281) Links for this episode Bat-filled tree (Science) Possible Ebola virus lab exposure (CIDRAP) Mishandling of Ebola virus sample (NY Times) Where could Ebola virus strike next? (NPR) New Legos of female scientists Photo and cookie by Kathy Spindler Letters read on TWiV 318 Weekly Science Picks Alan - Mystery photos from CERNRich - Adam E. Cohen: Bringing bioelectricity to lightKathy - Wired's top microbe stories of 2014Dickson - Mouse jokeVincent - The Science of Epidemics (Time Inc Special) Listener Pick of the Week Neva - Sir BacteriophageSagi - An unboring polio documentary Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv
Everything dinosaur is discussed. 60 seconds science focuses on specific fan favorite dinosaurs like brontosaurus, triceratops, and tyrannosaurus rex. The Basic Biology of dinosaurs, such as cold-blooded versus warm-blooded is included. The story of the mass extinction event that may or may not have involved the KT asteroid impact is told. The velociraptor and the tyrannosaurus rex have various myths replaced with truth such as the fact that they had feathers and attacked with their feet. Are you curious about if dinosaurs tickled each other? The relationship between birds and dinosaurs is highlighted. The discussion is the controversy of resurrecting dinosaurs Jurassic Park style and the scientific ethics is part of a round table.
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler The TWiV gang answer follow-up questions about the Ebola virus outbreak in West Africa, then discuss treatment of disseminated multiple myeloma with oncolytic measles virus. Links for this episode Use of unregistered interventions for Ebola virus disease (WHO) Response to anthrax and H5N1 incidents (CDC) Remission of disseminated cancer after treatment with oncolytic measles virus (Mayo Clin Proc) New viruses for cancer therapy (Nat Rev Micro) Cattaneo on TWiV Image credit Letters read on TWiV 298 Weekly Science Picks Alan - WTF, Evolution?! by Mara GrunbaumRich - Cold Spring Harbor Oral History CollectionKathy - Inside insidesVincent - Going Viral (Rocky Mountain Ballet Theatre) Listener Pick of the Week Kim - Nobel Prize PodcastsJohnye - The Planet is FineJennie - Counter-Zombie Dominance Plan (pdf) Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv
Winnie M. Chan and Grant McFadden of the Department of Molecular Genetics and Microbiology, University of Florida, introduce their article for the 2014 Annual Review of Virology, titled "Oncolytic Poxviruses."
Brains, Psychics, Artificial Intelligence, and How To Win at Rock, Paper, Scissors is the fourth episode. We talk about how the brain influences behavior, how you can trick your memory into remembering better, we debate nature versus nurture, and I tell you how to be a veritable psychic and win at rock, paper, scissors. Ken Jennings, jeopardy, and Waston are discussed at length. Sixty second sciences include seasonal affective disorder, implanting false memories, music and the brain, chronic traumatic brain injury in professional sports and its relation to Alzheimer's and Parkinson's, and Cerebral Palsy. Commercials include Sing-Along Study Songs for Science, a certain point of view, the animal helmet, and more.
Vincent, Dickson, Alan, Rich, and Grant discuss a tanapoxvirus protein that inhibits tumor necrosis factor, purging tumors with myxoma virus, and destruction of the last known stocks of smallpox virus.
On episode #84 of the podcast This Week in Virology, Vincent and Rich spoke with Dave Bloom and Grant McFadden about their work on herpesviruses and poxviruses in this episode recorded before an audience at the University of Florida, Gainesville - home of the Gators. Host links Vincent Racaniello, Rich Condit, Dave Bloom, and Grant McFadden Links for this episode: Epigenetic modulation of herpes simplex virus gene expression (thanks, Matthew!) The Red Queen and Tierra virtual environment: article one, two, three (thanks, Jesper!) Hand-held HIV detector (thanks, Jim!) Anti-angiogenic cancer therapy combined with oncolytic virotherapy (thanks, Bill!) TWiV at UF Gainesville (jpg) Letters read on TWiV 84 Weekly science picks: Rich - Charles F. Littlewood photographs Vincent - Not so humble pie (thanks, Sophie!) Grant - The Strangest Man by Graham Farmelo David - Is Parkinson's Disease a prion disorder?
Vincent visits Scotch Plains – Fanwood High School and talks about viruses with high school biology students. Host links: Vincent Racaniello Links for this episode: Vincent’s presentation (pdf) Thank you letters Oncolytic reovirus Does rhinovirus interfere with influenza?
© 2020-2025 Ivy Podcast Discovery LLC
